CoChat

Clinicopathologic Features of Advanced Squamous NSCLC

Open access
Socinski, Mark A., Obasaju, Coleman, Gandara, David, Hirsch, Fred R., Bonomi, Philip, Bunn, Paul, Kim, Edward S., Langer, Corey J., Natale, Ronald B., Novello, Silvia, Paz-Ares, Luis, Pérol, Maurice, Reck, Martin, Ramalingam, Suresh S., Reynolds, Craig H., Spigel, David R., Stinchcombe, Thomas E., Wakelee, Heather, Mayo, Carlos, Thatcher, Nick · 2016 · Journal of Thoracic Oncology
Cited by 180

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2016.05.024

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 85

  1. Torre, 2015, Global cancer statistics, 2012, CA Cancer J Clin, 65, 87, 10.3322/caac.21262 · DOI · Paper page
  2. Villaruz, 2013, Personalizing therapy in advanced non-small cell lung cancer, Semin Respir Crit Care Med, 34, 822, 10.1055/s-0033-1358552 · DOI
  3. Travis, 2011, International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma, J Thorac Oncol, 6, 244, 10.1097/JTO.0b013e318206a221 · DOI · Paper page
  4. Zugazagoitia, 2014, The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects, J Thorac Dis, 6, S526
  5. Oliver, 2015, Squamous non-small cell lung cancer as a distinct clinical entity, Am J Clin Oncol, 38, 220, 10.1097/COC.0b013e3182a0e850 · DOI
  6. Morgensztern, 2009, Improving survival for stage IV non-small cell lung cancer: a surveillance, epidemiology, and end results survey from 1990 to 2005, J Thorac Oncol, 4, 1524, 10.1097/JTO.0b013e3181ba3634 · DOI
  7. Cetin, 2011, Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program, Clin Epidemiol, 3, 139, 10.2147/CLEP.S17191 · DOI · Paper page
  8. Hirsch, 2008, The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review, J Thorac Oncol, 3, 1468, 10.1097/JTO.0b013e318189f551 · DOI · Paper page
  9. Scagliotti, 2010, Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer, J Clin Oncol, 28, 1835, 10.1200/JCO.2009.26.1321 · DOI · Paper page
  10. Socinski, 2012, Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial, J Clin Oncol, 30, 2055, 10.1200/JCO.2011.39.5848 · DOI · Paper page
  11. Travis, 2015, The 2015 World Health Organization Classification of Lung Tumors: impact of genetic, clinical and radiologic advances since the 2004 classification, J Thorac Oncol, 10, 1243, 10.1097/JTO.0000000000000630 · DOI · Paper page
  12. Thunnissen, 2012, The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group, Lung Cancer, 76, 1, 10.1016/j.lungcan.2011.10.017 · DOI · Paper page
  13. Terry, 2010, Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples, Am J Surg Pathol, 34, 1805, 10.1097/PAS.0b013e3181f7dae3 · DOI · Paper page
  14. Hallack Neto, 2009, p63 protein expression in high risk diffuse large B-cell lymphoma, J Clin Pathol, 62, 77, 10.1136/jcp.2008.059519 · doi:10.1136/jcp.2008.059519
  15. Bishop, 2012, p40 (δNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma, Mod Pathol, 25, 405, 10.1038/modpathol.2011.173 · DOI · Paper page
  16. Loo, 2010, Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens, J Thorac Oncol, 5, 442, 10.1097/JTO.0b013e3181d40fac · DOI · Paper page
  17. Gruver, 2012, Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung, Arch Pathol Lab Med, 136, 1339, 10.5858/arpa.2011-0575-OA · doi:10.5858/arpa.2011-0575-oa
  18. Rosado-de-Christenson, 1994, Bronchogenic carcinoma: radiologic-pathologic correlation, Radiographics, 14, 429, 10.1148/radiographics.14.2.8190965 · doi:10.1148/radiographics.14.2.8190965
  19. Gill, 2010, Cavities in the lung in oncology patients: imaging overview and differential diagnoses, Applied Radiology, 39, 10, 10.37549/AR1757 · doi:10.37549/ar1757
  20. Nichols, 2012, Causes of death of patients with lung cancer, Arch Pathol Lab Med, 136, 1552, 10.5858/arpa.2011-0521-OA · DOI
  21. Wilson, 2012, Doubling times and CT screen-detected lung cancers in the Pittsburgh Lung Screening Study, Am J Respir Crit Care Med, 185, 85, 10.1164/rccm.201107-1223OC · DOI
  22. Ito, 2012, Risk factors associated with fatal pulmonary hemorrhage in locally advanced non-small cell lung cancer treated with chemoradiotherapy, BMC Cancer, 12, 27, 10.1186/1471-2407-12-27 · DOI
  23. Dela Cruz, 2011, Lung cancer: epidemiology, etiology, and prevention, Clin Chest Med, 32, 605, 10.1016/j.ccm.2011.09.001 · DOI · Paper page
  24. Peto, 2000, Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies, BMJ, 321, 323, 10.1136/bmj.321.7257.323 · DOI · Paper page
  25. Duarte, 2008, The cigarette burden (measured by the number of pack-years smoked) negatively impacts the response rate to platinum-based chemotherapy in lung cancer patients, Lung Cancer, 61, 244, 10.1016/j.lungcan.2007.12.008 · doi:10.1016/j.lungcan.2007.12.008
  26. Fox, 2004, The effect of smoking status on survival following radiation therapy for non-small cell lung cancer, Lung Cancer, 44, 287, 10.1016/j.lungcan.2003.11.012 · DOI
  27. Papi, 2004, COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma, Thorax, 59, 679, 10.1136/thx.2003.018291 · DOI · Paper page
  28. Radzikowska, 2002, Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases, Ann Oncol, 13, 1087, 10.1093/annonc/mdf187 · DOI · Paper page
  29. Carter, 2015, Smoking and mortality—beyond established causes, N Engl J Med, 372, 631, 10.1056/NEJMsa1407211 · DOI · Paper page
  30. Youlden, 2008, The International Epidemiology of Lung Cancer: geographical distribution and secular trends, J Thorac Oncol, 3, 819, 10.1097/JTO.0b013e31818020eb · DOI · Paper page
  31. Schroeder, 2010, Don't forget tobacco, N Engl J Med, 363, 201, 10.1056/NEJMp1003883 · DOI
  32. Moyer, 2014, Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement, Ann Intern Med, 160, 330
  33. Pinsky, 2013, The National Lung Screening Trial: results stratified by demographics, smoking history and lung cancer histology, Cancer, 119, 3976, 10.1002/cncr.28326 · DOI · Paper page
  34. Frauenfelder, 2014, Early detection of lung cancer: a statement from an expert panel of the Swiss university hospitals on lung cancer screening, Respiration, 87, 254, 10.1159/000357049 · doi:10.1159/000357049
  35. Prosch, 2014, Screening for lung cancer, Curr Opin Oncol, 26, 131, 10.1097/CCO.0000000000000055 · DOI
  36. Devesa, 2005, International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising, Int J Cancer, 117, 294, 10.1002/ijc.21183 · DOI · Paper page
  37. Houston, 2014, Patterns in lung cancer incidence rates and trends by histologic type in the United States, 2004-2009, Lung Cancer, 86, 22, 10.1016/j.lungcan.2014.08.001 · DOI · Paper page
  38. Sakurai, 2010, Survival differences by gender for resected non-small cell lung cancer: a retrospective analysis of 12,509 cases in a Japanese Lung Cancer Registry study, J Thorac Oncol, 5, 1594, 10.1097/JTO.0b013e3181f1923b · DOI
  39. Visbal, 2004, Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002, Ann Thorac Surg, 78, 209, 10.1016/j.athoracsur.2003.11.021 · DOI · Paper page
  40. Nadpara, 2015, Guideline-concordant lung cancer care and associated health outcomes among elderly patients in the United States, J Geriatr Oncol, 6, 101, 10.1016/j.jgo.2015.01.001 · DOI
  41. Aarts, 2015, Improvement in population-based survival of stage IV NSCLC due to increased use of chemotherapy, Int J Cancer, 136, E387, 10.1002/ijc.29216 · DOI
  42. Janssen-Heijnen, 1998, Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study, Lung Cancer, 21, 105, 10.1016/S0169-5002(98)00039-7 · DOI · Paper page
  43. Asmis, 2008, Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials, J Clin Oncol, 26, 54, 10.1200/JCO.2007.12.8322 · DOI · Paper page
  44. Jørgensen, 2012, Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality, Br J Cancer, 106, 1353, 10.1038/bjc.2012.46 · DOI · Paper page
  45. Lee, 2013, Indirectly estimated absolute lung cancer mortality rates by smoking status and histological type based on a systematic review, BMC Cancer, 13, 189, 10.1186/1471-2407-13-189 · DOI
  46. Søgaard, 2013, The impact of comorbidity on cancer survival: a review, Clin Epidemiol, 5, 3, 10.2147/CLEP.S47150 · DOI · Paper page
  47. Wang, 2014, Detection of ALK protein expression in lung squamous cell carcinomas by immunohistochemistry, J Exp Clin Cancer Res, 33, 109, 10.1186/s13046-014-0109-2 · doi:10.1186/s13046-014-0109-2
  48. Forbes, 2008, The Catalogue of Somatic Mutations in Cancer (COSMIC), Curr Protoc Hum Genet, 10.1002/0471142905.hg1011s57 · DOI · Paper page
  49. Caliò, 2014, ALK/EML4 fusion gene may be found in pure squamous carcinoma of the lung, J Thorac Oncol, 9, 729, 10.1097/JTO.0000000000000109 · DOI
  50. Rekhtman, 2012, Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations, Clin Cancer Res, 18, 1167, 10.1158/1078-0432.CCR-11-2109 · DOI · Paper page
  51. Liao, 2012, Targeted therapy for squamous cell lung cancer, Lung Cancer Manag, 1, 293, 10.2217/lmt.12.40 · DOI
  52. Pao, 2011, New driver mutations in non-small-cell lung cancer, Lancet Oncol, 12, 175, 10.1016/S1470-2045(10)70087-5 · DOI · Paper page
  53. Kim, 2014, Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients, J Clin Oncol, 32, 121, 10.1200/JCO.2013.50.8556 · DOI · Paper page
  54. Hirsch, 2003, Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis, J Clin Oncol, 21, 3798, 10.1200/JCO.2003.11.069 · DOI · Paper page
  55. Pirker, 2012, EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study, Lancet Oncol, 13, 33, 10.1016/S1470-2045(11)70318-7 · DOI · Paper page
  56. Thatcher, 2015, Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial, Lancet Oncol, 16, 763, 10.1016/S1470-2045(15)00021-2 · DOI · Paper page
  57. Pirker, 2012, Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study, Lung Cancer, 77, 376, 10.1016/j.lungcan.2012.03.010 · DOI
  58. Young, 2015, Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo, Target Oncol, 10, 501, 10.1007/s11523-014-0353-6 · DOI
  59. Dutt, 2011, Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer, PLoS One, 6, e20351, 10.1371/journal.pone.0020351 · DOI · Paper page
  60. Heist, 2012, FGFR1 amplification in squamous cell carcinoma of the lung, J Thorac Oncol, 7, 1775, 10.1097/JTO.0b013e31826aed28 · DOI · Paper page
  61. Gadgeel, 2013, Fibroblast growth factor receptor 1 amplification in non-small cell lung cancer by quantitative real-time PCR, PLoS One, 8, e79820, 10.1371/journal.pone.0079820 · DOI
  62. Sos, 2012, Genetic insight and therapeutic targets in squamous-cell lung cancer, Oncogene, 31, 4811, 10.1038/onc.2011.640 · DOI
  63. Weiss, 2010, Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous-cell lung cancer, Sci Transl Med, 2, 10.1126/scitranslmed.3001451 · DOI · Paper page
  64. Paik, 2014, A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: Preliminary antitumour activity and pharmacodynamic data [abstract], J Clin Oncol, 32, 8035, 10.1200/jco.2014.32.15_suppl.8035 · doi:10.1200/jco.2014.32.15_suppl.8035
  65. Nogova, 2014, Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398 [abstract], J Clin Oncol, 32, 8034, 10.1200/jco.2014.32.15_suppl.8034 · doi:10.1200/jco.2014.32.15_suppl.8034
  66. Wynes, 2014, FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies, Clin Cancer Res, 20, 3299, 10.1158/1078-0432.CCR-13-3060 · DOI
  67. Okudela, 2007, PIK3CA mutation and amplification in human lung cancer, Pathol Int, 57, 664, 10.1111/j.1440-1827.2007.02155.x · DOI · Paper page
  68. Heist, 2012, Genetic changes in squamous cell lung cancer: a review, J Thorac Oncol, 7, 924, 10.1097/JTO.0b013e31824cc334 · DOI · Paper page
  69. Vansteenkiste, 2015, Safety and efficacy of buparlisib (BKM120) in patients with PI3K pathway-activated non-small cell lung cancer: results from the phase II BASALT-1 study, J Thorac Oncol, 10, 1319, 10.1097/JTO.0000000000000607 · DOI · Paper page
  70. Hammerman, 2011, Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer, Cancer Discov, 1, 78, 10.1158/2159-8274.CD-11-0005 · DOI · Paper page
  71. Miao, 2014, Identification of novel driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lung cancer of Chinese patients, BMC Cancer, 14, 369, 10.1186/1471-2407-14-369 · DOI
  72. Brunner, 2013, Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung, J Thorac Oncol, 8, 1434, 10.1097/JTO.0b013e3182a47162 · DOI
  73. Shibata, 2010, Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway, Cancer Res, 70, 9095, 10.1158/0008-5472.CAN-10-0384 · DOI · Paper page
  74. Kim, 2009, Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration, Lung, 187, 401, 10.1007/s00408-009-9181-3 · DOI
  75. Vansteenkiste J, Cho BC, Vanakesa T, et al. MAGRIT, a double-blind, randomized, placebo-controlled phase III study to assess the efficacy of the recMAGE-A3 + AS15 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small cell lung cancer (NSCLC). Abstract 1173O presented at the 2014 European Society Medical Oncology Congress. September 26–30, 2014; Madrid, Spain. · DOI
  76. Ikeda, 2006, Clinicopathologic roles of tumor-infiltrating lymphocytes and CD8-positive lymphocytes in lung cancer imprint smears in squamous cell carcinoma and adenocarcinoma, Acta Cytol, 50, 423, 10.1159/000325986 · doi:10.1159/000325986
  77. Yoshida, 2006, Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance, Int J Oncol, 28, 1089
  78. da Costa Souza, 2012, Different morphology, stage and treatment affect immune cell infiltration and long-term outcome in patients with non-small-cell lung carcinoma, Histopathology, 61, 587, 10.1111/j.1365-2559.2012.04318.x · DOI
  79. Kitazono, 2015, Reliability of small biopsy samples compared with resected specimens for the determination of programmed death-ligand 1 expression in non-small-cell lung cancer, Clin Lung Cancer, 16, 385, 10.1016/j.cllc.2015.03.008 · DOI
  80. Velcheti, 2014, Programmed death ligand-1 expression in non-small cell lung cancer, Lab Invest, 94, 107, 10.1038/labinvest.2013.130 · DOI · Paper page
  81. D'Incecco, 2015, PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients, Br J Cancer, 112, 95, 10.1038/bjc.2014.555 · DOI · Paper page
  82. Rebelatto, 2015, Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients, J Clin Oncol, 3, 8033, 10.1200/jco.2015.33.15_suppl.8033 · DOI · Paper page
  83. Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690 · DOI · Paper page
  84. Brahmer, 2015, KEYNOTE-024: phase III trial of pembrolizumab (MK-3475) vs platinum-based chemotherapy as first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) that expresses programmed cell death ligand 1 (PD-L1), J Clin Oncol, 33, TPS8103, 10.1200/jco.2015.33.15_suppl.tps8103 · doi:10.1200/jco.2015.33.15_suppl.tps8103
  85. Kwak, 2010, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer, N Engl J Med, 363, 1693, 10.1056/NEJMoa1006448 · DOI · Paper page

Cited by

See all 180

Metadata

Authors
Socinski, M. A., Obasaju, C., Gandara, D., Hirsch, F. R., Bonomi, P., Bunn, P., Kim, E. S., Langer, C. J., Natale, R. B., Novello, S., Paz-Ares, L., Pérol, M., Reck, M., Ramalingam, S. S., Reynolds, C. H., Spigel, D. R., Stinchcombe, T. E., Wakelee, H., Mayo, C., & Thatcher, N.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2016-09
Volume
11
Issue
9
Pages
1411-1422
ISSN
1556-0864 (ISSN-L)
OpenAlex
W2416190981
Cited by
180
References
16
FWCI
5.03
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.